Enlivex Therapeutics Ltd (ENLV : NASDAQ)
Common Stock
$2.70
USD
+2.53 (1460.69%)
Last updated: 2026-10-27
Stock Reverse Split
YesterdayThis stock executed a 1-for-16 reverse split on October 27, 2026. Historical prices have been adjusted accordingly.
Follow ENLV
ENLV
Enlivex Therapeutics Ltd
Performance
1 Day
+1460.69%
1 Week
-24.56%
1 Month
-71.76%
YTD
-98.18%
Key Statistics
Market Cap
$4.14M
52W High
$316.80
52W Low
$0.17
P/E Ratio
0.00
50 Day MA
$12.24
200 Day MA
$141.83
Beta
1.41
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/27/2026 | $2.56 | $2.89 | $2.21 | $2.70 | $2.70 | 79,959 |
| 10/26/2026 | $0.17 | $0.17 | $0.17 | $0.17 | $0.17 | 24,849 |
| 10/23/2026 | $0.17 | $0.18 | $0.17 | $0.17 | $0.17 | 655,100 |
| 10/22/2026 | $0.20 | $0.20 | $0.19 | $0.20 | $0.20 | 525,100 |
| 10/21/2026 | $0.22 | $0.23 | $0.20 | $0.20 | $3.24 | 46,602 |
| 10/20/2026 | $0.21 | $0.23 | $0.21 | $0.22 | $3.58 | 27,969 |
| 10/19/2026 | $0.21 | $0.23 | $0.19 | $0.21 | $3.32 | 37,964 |
| 10/16/2026 | $0.23 | $0.23 | $0.20 | $0.20 | $3.28 | 29,980 |
| 10/15/2026 | $0.22 | $0.24 | $0.21 | $0.22 | $3.59 | 35,020 |
| 10/14/2026 | $0.22 | $0.23 | $0.21 | $0.22 | $3.45 | 34,817 |
Analyst Price Targets
Based on 1 analyst covering ENLV · as of Oct 27, 2026
Wall Street analysts forecast ENLV stock price to rise 47307.4% over the next 12 months.
Consensus
Strong Buy5.00 / 5.00
Avg. Target
US$1280.00
+47307.4% Upside
Previously US$80.00 on Oct 5, 2026
Current Price
US$2.70
Last close
Analyst Breakdown (1 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ENLV's historical volatility
30-Day Vol
1159.2%
Annualized
90-Day Vol
676.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
US$2.26
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$2.54 | US$0.05 – US$138.83 |
| 60 trading days | US$2.40 | US$0.01 – US$685.64 |
| 90 trading days | US$2.26 | US$0.00 – US$2303.12 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Enlivex Therapeutics Ltd
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-23.94M
- Profit Margin
- 0.00%
- ROE (TTM)
- 162.86%
- EPS (Diluted)
- 8320.65
- Book Value
- 3705.55
Classification
- Sector
- Information Technology
- Industry
- Software
- Group
- Software & Services
🔄 Recent Splits
1-for-16
Oct 27, 2026
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About ENLV.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| NUWE | Nuwellis Inc | $5.41 | +1590.63% |
| QETAR | Quetta Acquisition Corporation Right | $0.68 | +70.00% |
| BRAI | Braiin Limited Common Stock | $3.31 | +56.13% |
| IRHOR | Iron Horse Acquisitions Corp. II Rights | $0.14 | +49.83% |
| FSHPR | Flag Ship Acquisition Corp. Right | $0.10 | +47.06% |
| AEYE | AudioEye Inc | $10.14 | +36.66% |
| MBRX | Moleculin Biotech Inc | $9.27 | +30.77% |
| OWLS | OBOOK Holdings Inc. Class A Common Shares | $2.66 | +30.39% |